Welcome to our dedicated page for LENZ THERAPEUTICS SEC filings (Ticker: LENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LENZ Therapeutics, Inc. (Nasdaq: LENZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded pharmaceutical issuer focused on presbyopia treatment. LENZ uses its filings to report material events related to VIZZ (aceclidine ophthalmic solution) 1.44%, financial results, capital raising activities and other significant corporate developments.
For investors analyzing LENZ, periodic reports and current reports on Form 8-K are key sources of information. Recent 8-K filings referenced by the company include announcements of FDA approval of LNZ100 (VIZZ) for the treatment of presbyopia in adults, the availability of VIZZ in the United States, and preliminary financial results and commercial highlights following launch. Another 8-K describes a block sale of common stock under an at-the-market sales agreement, illustrating how LENZ has raised capital to support its operations and commercialization efforts.
LENZ also uses 8-K filings to furnish press releases with quarterly financial results, which detail items such as cash, cash equivalents and marketable securities, selling, general and administrative expenses, research and development expenses and net loss. While these specific figures change over time, the filings show how the company reports its financial condition and the impact of building a sales force and marketing infrastructure for VIZZ.
Safety-related disclosures can also appear in LENZ filings. In one 8-K, the company describes an adverse event report in the FDA’s FAERS database involving a retinal tear in a patient using VIZZ, outlines the patient’s pre-existing retinal risk factors and notes that a causal relationship to VIZZ remains uncertain. Such filings help investors understand how LENZ communicates about product safety as VIZZ use expands in real-world settings.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents, making it easier to review items such as quarterly earnings releases, product approval announcements, capital markets transactions and safety updates. Users can track new 8-Ks and other forms as they are filed with EDGAR, and quickly identify disclosures most relevant to LENZ’s commercialization of VIZZ and its overall financial profile.
LENZ Therapeutics (LENZ) reported an insider purchase by its Chief Financial Officer, Daniel R. Chevallard. On 11/07/2025, he bought common stock in two open‑market transactions coded “P”: 20 shares at $22.71 and 2,178 shares at $22.7561. Following these trades, he directly owns 5,386 shares.
LENZ Therapeutics (LENZ) reported Q3 2025 results and highlighted FDA approval of VIZZ. The company recorded $12.5 million in license revenue in the quarter and $17.5 million year-to-date. Operating expenses rose with commercialization activities, led by selling, general and administrative of $27.6 million and research and development of $3.8 million, resulting in a net loss of $16.7 million (basic and diluted loss per share of $0.59).
LENZ ended September 30, 2025 with $202.2 million in cash, cash equivalents, and marketable securities and reported 28,540,519 weighted‑average shares outstanding for the quarter. The company sold 920,500 shares via its at‑the‑market program during the nine months ended September 30, 2025 for $26.1 million in net proceeds, and subsequently sold 2,698,134 shares in October at a weighted‑average price of $45.79. On July 31, 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults.
LENZ Therapeutics, Inc. furnished a Form 8-K announcing its financial results for the quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, and incorporated by reference.
The Item 2.02 disclosure and the press release are furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act. Exhibits include the press release (99.1) and the cover page interactive data file (104).
Lenz Therapeutics, Inc. reported that it sold 1,748,634 shares of common stock on October 7, 2025 at a purchase price of $45.75 per share in a block trade to a single investor. The transaction generated gross proceeds of approximately $80,000,000 for the company. The sale was executed under the company’s existing “at the market” Sales Agreement with TD Securities (USA) LLC, dated April 4, 2025, and was completed pursuant to the terms of that agreement.
Versant entities reported insider sales of 224,974 shares of LENZ Therapeutics, Inc. (LENZ) on 09/30/2025. The Form 4 shows multiple sales by related reporting persons (including Versant Venture Capital VI, L.P. and affiliated Versant GP and Vantage entities) executed at weighted-average prices in ranges of $45.00–$45.99, $46.00–$46.99, and $47.00–$47.02. Post-transaction beneficial ownership amounts are disclosed for direct and indirect holdings, with several Versant entities retaining substantial positions (for example, 1,133,842 shares reported as directly owned by one entity and 842,162 shares indirectly held by another). The filing is signed by Max Eisenberg for the Versant reporting entities on 10/02/2025. The footnotes explain that reported prices are weighted averages from multiple transactions and identify the chain of general partners that may share voting and investment power over the disclosed holdings.
LENZ Therapeutics announced that VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop approved in the United States for treating presbyopia in adults, is now available. This medicine is intended to help adults with age-related difficulty focusing on near objects.
LENZ has begun distributing professional product samples nationwide through its sales force to optometrists and ophthalmologists so eye-care professionals can evaluate and introduce VIZZ to patients. Commercial product shipments to consumers will begin in October through an ePharmacy partner and are expected to expand to broad retail pharmacy availability by mid‑Q4 2025.
Versant entities reported multiple sales of LENZ Therapeutics common stock on 09/18/2025. The Form 4 shows a series of dispositions at weighted-average prices of $41.5908 (sales between $41.25 and $42.24) and $43.0038 (sales between $42.25 and $43.24), plus small sales at $43.30.
Reported transactions include direct and indirect sales: for example, 49,479 and 40,907 shares sold directly and 24,370 and 20,148 shares sold indirectly across the two weighted-average-price groups. The filings list 1,224,718; 1,183,811; and related post-transaction beneficial ownership totals for the reporting entities, and note 842,162 shares held indirectly by Versant Vantage II, L.P.
Versant investment funds disclosed holdings and recent sales of LENZ Therapeutics common stock. Multiple Versant entities report beneficial ownership stakes of 1,183,543 shares (4.1%) for Versant VI, 842,162 shares (3.0%) for Versant Vantage II, and 926,691 shares (3.2%) for Versant VII (the latter includes 70,534 shares issuable on a warrant). The filing lists a series of open-market dispositions in August and September 2025 by Versant VI and Versant VII, including sales on August 22, August 25, August 26 and September 18, 2025 that generated aggregate proceeds in the low millions on each date (examples: Versant VI sold 90,654 shares on September 18, 2025 for approximately $3,828,631.71; Versant VII sold 44,650 shares that same date for approximately $1,885,723.80). The Amendment updates Item 5 of the prior Schedule 13D filings and states that only the amended items are changed, leaving prior disclosures unchanged.
Versant entities reported multiple sales of LENZ Therapeutics common stock on August 22, 25 and 26, 2025. The filing lists a series of non-derivative sales totaling 188,094 shares across those dates at weighted-average prices in ranges between $38.50 and $40.8819 per share. The reporting parties include Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P. and Versant Vantage II, L.P., and related general partner and GP-GP entities. Footnotes state that certain holdings are held indirectly by VVC VI, VVC VII and VV II, and that the reporting entities may be deemed to share voting, investment and dispositive power over those shares. The Form 4 is signed by Max Eisenberg as Chief Operating Officer for the reporting entities.
Amendment No. 7 to a Schedule 13D reports ownership and recent sales of LENZ Therapeutics, Inc. common stock by multiple Versant-related entities. The filing lists Versant Venture Capital VI, L.P. (Versant VI) as holding 1,400,220 shares, representing 4.9% of the outstanding shares (based on 28,522,096 shares reported as of July 24, 2025). Versant Vantage II, L.P. holds 842,162 shares (3.0%). Versant Venture Capital VII, L.P. holds 1,033,412 shares (including a warrant for 70,534 shares), representing 3.6% on an adjusted basis.
The Amendment discloses share sales: on August 15, 2025 Versant VI sold 145,051 shares at $39.50 per share (proceeds ~$5,729,514.50) and Versant VII sold 69,949 shares at $39.50 (proceeds ~$2,762,985.50). On August 18, 2025 Versant VI sold 30,628 shares at a weighted average $38.5611 (proceeds ~$1,181,049.37) and Versant VII sold 15,085 shares at the same weighted average (proceeds ~$581,694.19). The Amendment updates cover-page holdings and clarifies related general partner relationships; other items from the original Schedule 13D remain unchanged.